Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis

NCT01262118 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01262118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01262118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
February 29, 2012
Enrollment
69 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis